Nicardipine Laboratoire Aguettant (Nicardipine Hydrochloride)

Nicardipine Hydrochloride blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium entry. This causes arterial vasodilation, lowers peripheral resistance, reduces blood pressure, and improves coronary blood flow, thereby alleviating angina.

The dosage of nicardipine is individualized. The prescribing clinician determines the infusion rate and total dose based on the patient’s condition, blood‑pressure response, and relevant clinical guidelines.

Safety of nicardipine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

Enquiries are submitted on the product page at gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import paperwork.

Nicardipine is a short‑acting, intravenous dihydropyridine calcium‑channel blocker, offering rapid titratable blood‑pressure control. Compared with oral agents such as amlodipine, it acts faster and is suitable for critical‑care settings. Unlike nitroprusside, it has a lower risk of cyanide toxicity and provides more predictable dosing.

Store the solution at controlled room temperature, below 25 °C. Keep it in the original packaging, protect from moisture and light, and do not freeze. Follow standard aseptic handling procedures when preparing the infusion.

Nicardipine is given as an intravenous infusion. The solution is typically diluted in a compatible IV fluid and administered over a prescribed period under continuous blood‑pressure and cardiac monitoring.

The most serious adverse events include severe hypotension, myocardial infarction, and cardiac arrhythmias such as atrioventricular block. Prompt recognition and management of these events are essential during therapy.

Nicardipine is contraindicated in patients with known hypersensitivity to the drug, severe aortic stenosis, uncontrolled heart failure, or in shock states where rapid blood‑pressure reduction could be harmful.